04388nam 22006015 450 991073372780332120200706201612.03-319-13081-110.1007/978-3-319-13081-1(CKB)3710000000372121(EBL)1997866(OCoLC)904597987(SSID)ssj0001465000(PQKBManifestationID)11902199(PQKBTitleCode)TC0001465000(PQKBWorkID)11458503(PQKB)10125618(DE-He213)978-3-319-13081-1(MiAaPQ)EBC1997866(PPN)184890306(EXLCZ)99371000000037212120150305d2015 u| 0engur|n|---|||||txtccrAntibody-Drug Conjugates The 21st Century Magic Bullets for Cancer /edited by Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro1st ed. 2015.Cham :Springer International Publishing :Imprint: Springer,2015.1 online resource (248 p.)AAPS Advances in the Pharmaceutical Sciences Series,2210-7371 ;17Description based upon print version of record.3-319-13080-3 Includes bibliographical references and index at the end of each chapters.1 Antibody-Drug Conjugates: A Historical Review -- 2 Payloads of Antibody-Drug Conjugates -- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy -- 4 Linker Design for Antibody-Drug Conjugates -- 5 Formulation Development for Antibody-Drug Conjugates -- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates -- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates -- 8 Regulatory Considerations -- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy -- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal -- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate -- 12 Ado-Trastuzumab Emtansine -- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer -- 14 Summary and Future Directions.This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.AAPS Advances in the Pharmaceutical Sciences Series,2210-7371 ;17Pharmaceutical technologyPharmaceutical Sciences/Technologyhttps://scigraph.springernature.com/ontologies/product-market-codes/B21010Pharmaceutical technology.Pharmaceutical Sciences/Technology.615.36Wang Jeffreyedthttp://id.loc.gov/vocabulary/relators/edtShen Wei-Chiangedthttp://id.loc.gov/vocabulary/relators/edtZaro Jennica Ledthttp://id.loc.gov/vocabulary/relators/edtMiAaPQMiAaPQMiAaPQBOOK9910733727803321Antibody-drug conjugates2231062UNINA02886oam 2200793 c 450 991096290620332120200115203623.0978661287559597814742118881474211887978128287559312828755909781441168290144116829X10.5040/9781474211888(CKB)2670000000055999(EBL)601481(OCoLC)676698610(SSID)ssj0000421553(PQKBManifestationID)12147417(PQKBTitleCode)TC0000421553(PQKBWorkID)10412608(PQKB)10617959(MiAaPQ)EBC601481(Au-PeEL)EBL601481(CaPaEBR)ebr10427402(CaONFJC)MIL287559(OCoLC)893334926(OCoLC)1138648043(UtOrBLW)bpp09257584(UtOrBLW)BP9781474211888BC(Perlego)806373(EXLCZ)99267000000005599920101008d2010 uy 0engur|n|---|||||txtccrKey terms in systemic functional linguistics Christian M.I.M. Matthiessen, Kazuhiro Teruya and Marvin Lam1st ed.London New York Continuum 2010.1 online resource (321 p.)Key terms seriesDescription based upon print version of record.9781847064394 1847064396 9781847064400 184706440X Includes bibliographical references (pages [273]-295) and index1. Introduction to Key Terms in SFL -- 2. Key Terms -- Bibliography -- The field of Systemic Functional Linguistics is a social semiotic approach to language pioneered by M. A. K. Halliday, which has assumed a central importance in linguistics in recent years, anchored by a growing body of work. This book details the key terms, the key thinkers and the key texts in this field in an approachable, easy to understand and accessible manner. It is authored by leading names in the field and is aimed at undergraduates and postgraduates studying linguistics and language studies. Key terms series.Functionalism (Linguistics)Semantics, discourse analysis, etcSystemic grammarFunctionalism (Linguistics)Systemic grammar.410.18Matthiessen Christian M. I. M.977030Teruya KazuhiroLam MarvinUtOrBLWUtOrBLWUkLoBPBOOK9910962906203321Key terms in systemic functional linguistics4478143UNINA